Stockreport

Praxis Precision Medicines Inc (PRAX) Reports Full-Year 2023 Financial Results and Corporate Updates [Yahoo! Finance]

Praxis Precision Medicines, Inc.  (PRAX) 
PDF Research and Development : R&D expenses decreased to $86.8 million in 2023 from $155.0 million in 2022, reflecting strategic focus and operational efficiencies. Gener [Read more]